Efficacy and Safety of Methylprednisolone Per os Versus IV for the Treatment of Multiple Sclerosis (MS) Relapses

Inclusion Criteria: * age 18 to 55 * informed written consent * multiple sclerosis (Mc Donald criteria, relapsing-remitting * EDSS before relapse : 0 to 5 * relapse : increase of 1 point or more for 1 or more functional systems of Kurtzke, with SF score most affected \> 1 for all functions except for sensory (\> 2); duration of symptoms \> 24 h Exclusion Criteria: * fever * previous relapse, and/or corticosteroid treatment \< 1 month before present relapse * first symptoms of the present relapse appeared \> 15 days before inclusion * under mitoxantrone of cyclophosphamid or natalizumab treatment * diabetes * infection not under control * liver or kidney failure * psychiatric symptoms not under control * pregnancy * hypersensibility to methylprednisolone